Skip to main content
UniHealth

Doctor search

Mandar A Aras, MD

Cardiovascular Disease (Cardiology) · San Francisco

NPI 1720377146

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
9
1 carrier
Offices
2
Since medical school
15 years
University of Pittsburgh School of Medicine, 2011

Offices

2 locations · University of California San Francisco · Regents of the University of California

Looking this up.

Hospitals listed: Marinhealth Medical Center · UCSF Medical Center. That is not proof they admit you there this week.

Plans that list them

9 plans · 1 carrier

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Aras’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026

California Medical Board record

Licence A130155 · Current

Licensed to practise in California · since 2014 · expires 2027-10-31 · University of Pittsburgh School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

School, training and certification

What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.

Specialty certification

  • American Board of Internal Medicine - Advanced Heart Failure and Transplant
  • American Board of Internal Medicine - Cardiovascular Disease

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Marinhealth Medical CenterGreenbrae, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of MarinHealthPatients rate it 3 of 5 · 76% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.66 (3.59 to 7.73) · 1,505 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.177, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025
  • UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend it
    Overall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Marinhealth Medical Center

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 3 better, 8 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Marinhealth Medical Center
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.66 (3.59 to 7.73) · 1,505 casesWorseJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.177BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.85 (0 to 1.83) · 1,056 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.04 (0.72 to 1.36)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths167.34 (112.58 to 222.09) · 57 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.9 · 47 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths8.5 · 119 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.6 · 257 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.5 · 428 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths11.4 · 477 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths9.3 · 197 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3.1 · 2,827 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.18 (0 to 0.38) · 6,990 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.21 (0.02 to 0.41) · 6,838 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.41 (0 to 3) · 664 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.86 (1.4 to 4.33) · 1,436 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths10.38 (3.68 to 17.08) · 705 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths4.38 (0.72 to 8.04) · 672 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.66 (0.18 to 3.15) · 300 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.56 (0 to 1.25) · 5,550 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.4 · 76 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.396No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.1 · 275 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits22 · 427 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-20.3 · 289 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits3.3 · 494 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-4.9 · 499 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits17.9 · 435 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.5 (3.6 to 8.4) · 93 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits11.2 (7.8 to 16) · 93 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits6.6 · 84 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.5 · 53 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.3 · 111 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13 (10.3 to 16.5) · 2,119 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1.1 (0.8 to 1.4) · 670 casesNo differentJan 2024 – Dec 2024

What patients said (1,233 patients answered, 19% of those asked)

Patient survey stars by topic at Marinhealth Medical Center
Cleanliness3
Nurse communication3
Doctor communication3
Communication about medicines2
Discharge information3
Overall hospital rating4
Quietness3
Recommend hospital4
Share of patients giving the best answer at Marinhealth Medical Center
Room was "always" clean68%
Nurses "always" communicated well73%
Doctors "always" communicated well74%
Staff "always" explained56%
Yes, staff "did" give patients this information85%
Yes, staff "did" give patients information about help after discharge85%
Doctors "always" explained things so they could understand71%
Doctors "always" listened carefully72%
Doctors "always" treated them with courtesy and respect80%
Patients who gave a rating of "9" or "10" (high)72%
Staff "always" explained new medications70%
Nurses "always" explained things so they could understand68%
Nurses "always" listened carefully68%
Nurses "always" treated them with courtesy and respect82%
"Always" quiet at night48%
"YES", patients would definitely recommend the hospital76%
Staff "always" explained possible side effects43%
Yes, staff "did" give patients information about possible symptoms85%
See every measure and the patient survey for UCSF Medical Center

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at UCSF Medical Center
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths4.9 (3.79 to 6.02) · 7,590 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits12.8 (11.3 to 14.4) · 2,019 casesWorseJan 2024 – Dec 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths139.4 (110.22 to 168.58) · 452 casesBetterJul 2022 – Jun 2024
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.622BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.626BetterOct 2024 – Sep 2025
MRSA BacteremiaInfections0.491BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.8 (0.7 to 1) · 2,336 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.24 (0.58 to 1.9) · 4,689 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.05 (0.89 to 1.2)No differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.9 · 89 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths7.5 · 85 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths10.1 · 132 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.6 · 454 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 618 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths9.6 · 380 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.7 · 5,000 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.22 (0.06 to 0.38) · 15,965 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.2 (0.05 to 0.35) · 17,859 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.85 (0 to 1.83) · 4,184 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2 (1.1 to 2.9) · 6,516 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths7.35 (4.49 to 10.21) · 3,989 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5 (3.22 to 6.77) · 4,087 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.95 (0.74 to 3.15) · 2,034 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.95 (0.63 to 1.28) · 15,431 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 399 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.899No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.689No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections1.224No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16 · 156 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20 · 564 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits60.3 · 160 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-9.7 · 550 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits44.1 · 660 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.8 · 667 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.7 (4.8 to 6.7) · 2,019 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits6 · 421 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.5 · 53 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20 · 107 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13.9 (11.3 to 17.1) · 3,247 casesNo differentJan 2022 – Dec 2024

What patients said (3,181 patients answered, 25% of those asked)

Patient survey stars by topic at UCSF Medical Center
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at UCSF Medical Center
Room was "always" clean71%
Nurses "always" communicated well80%
Doctors "always" communicated well80%
Staff "always" explained61%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge87%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)76%
Staff "always" explained new medications75%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully78%
Nurses "always" treated them with courtesy and respect86%
"Always" quiet at night50%
"YES", patients would definitely recommend the hospital81%
Staff "always" explained possible side effects46%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$82,619

Medicare paid this office $82,619 for 316 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)151$24,138$119
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes41$18,483$105
New patient visit (60+ min)68$10,505$154
Biopsy of heart muscle14$3,220$189
Long return visit (40+ min)13$3,169$158
See all 9 services
Every Original Medicare service billed
Long return visit (40+ min)151$24,138$119
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes41$18,483$105
New patient visit (60+ min)68$10,505$154
Biopsy of heart muscle14$3,220$189
Long return visit (40+ min)13$3,169$158
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's138$2,499$15
Test for exercise-induced heart and lung stress35$2,021$58
Initial hospital care with moderate level of medical decision making at least 75 minutes13$1,997$154
Evaluation of lower heart chamber assist device16$1,671$29

Who their Medicare patients are

316 Original Medicare patients in 2024. Average age 71 · Under 65 21% · 85 and older 9% · Women 35% · Also on Medicaid 31% · Health risk score 2.98. Sicker patients than 9 in 10 peers; the typical cardiology clinician is at 1.71.

Conditions among them: High blood pressure 75% · Heart failure 75% · Chronic kidney disease 56% · Coronary heart disease 54% · Atrial fibrillation 51% · Diabetes 41% · Depression 26% · Cancer 22% · COPD 20% · Stroke 14% · Dementia 5%.

The office billed $569,957, Medicare allowed $107,740 and paid $82,619; for 1,615 services of 42 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20243161,615712.98$569,957$82,619
20233012,186702.78$459,946$74,001
2022259600692.92$396,085$62,916
2021237631683.02$369,592$56,169
2020238682662.87$399,052$56,558
2019247733653.06$437,186$61,532
2018137346662.60$210,593$30,906

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 6 services

Original Medicare services billed in 2023
Long return visit (40+ min)131$22,066$125
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes31$19,829$107
New patient visit (60+ min)75$11,483$153
Test for exercise-induced heart and lung stress58$3,557$60
Biopsy of heart muscle16$3,297$194
Test to measure expiratory airflow and volume changes before and after medication administration26$236$9

2022: 7 services

Original Medicare services billed in 2022
Long return visit (40+ min)126$22,518$127
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes37$14,278$91
New patient visit (60+ min)69$10,867$157
Insertion of tube in right heart chambers for measurement18$2,022$106
Test for exercise-induced heart and lung stress20$1,169$58
Telephone medical discussion with physician, 21-30 minutes11$969$88
Test to measure expiratory airflow and volume changes before and after medication administration17$146$9

2021: 8 services

Original Medicare services billed in 2021
Long return visit (40+ min)116$21,572$120
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes30$10,988$92
New patient visit (60+ min)54$8,651$160
Evaluation of lower heart chamber assist device18$4,357$34
Insertion of tube in right heart chambers for measurement19$1,905$95
Test for exercise-induced heart and lung stress30$1,860$62
Return visit (30+ min)11$862$62
Test to measure expiratory airflow and volume changes before and after medication administration31$280$9

2020: 10 services

Original Medicare services billed in 2020
Long return visit (40+ min)124$17,368$93
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes26$12,164$93
Evaluation of lower heart chamber assist device26$6,262$44
New patient visit (60+ min)42$6,118$146
Biopsy of heart muscle16$3,353$197
Return visit (30+ min)23$1,931$72
Insertion of tube in right heart chambers for measurement16$1,676$105
Telephone medical discussion with physician, 21-30 minutes12$928$71
Test to measure expiratory airflow and volume changes before and after medication administration24$285$12
Test to measure exhaled air and carbon dioxide for evaluation of lung function24$224$9

2019: 10 services

Original Medicare services billed in 2019
Long return visit (40+ min)125$17,685$94
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes40$14,809$92
Evaluation of lower heart chamber assist device25$7,318$41
New patient visit (60+ min)41$5,932$145
Critical care, first 30-74 minutes15$3,480$193
Biopsy of heart muscle11$3,335$176
Initial hospital care with moderate level of medical decision making at least 75 minutes13$2,327$179
Insertion of tube in right heart chambers for measurement19$2,136$107
Test to measure expiratory airflow and volume changes before and after medication administration26$304$11
Test to measure exhaled air and carbon dioxide for evaluation of lung function25$239$9

2018: 5 services

Original Medicare services billed in 2018
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes30$8,986$93
Long return visit (40+ min)55$7,638$97
New patient visit (60+ min)25$3,610$144
Evaluation of lower heart chamber assist device12$2,312$41
Insertion of tube in right heart chambers for measurement13$1,457$112

Medicaid work

$36,175 in 2024

Medicaid paid $36,175 for 256 billed services this clinician did in 2024, up to 27 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Long return visit (40+ min)208$32,623
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES48$3,551
Medicaid work by year
2024256227$36,175
2023266225$27,971
202287119$11,892
2021102316$9,631
202061218$5,050
2019125219$12,386
201829112$2,289
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Long return visit (40+ min)134$17,793
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES132$10,179

2022

Largest Medicaid services in 2022
Long return visit (40+ min)87$11,892

2021

Largest Medicaid services in 2021
Long return visit (40+ min)42$5,566
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES48$3,443
Telehealth originating site facility fee12$621

2020

Largest Medicaid services in 2020
Long return visit (40+ min)48$4,933
Telehealth transmission, per minute, professional services bill separately13$117

2019

Largest Medicaid services in 2019
Long return visit (40+ min)82$8,017
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES43$4,369

2018

Largest Medicaid services in 2018
Long return visit (40+ min)29$2,289

Drugs they prescribed that Part D paid

$8,446,299

Pharmacies billed $8,446,299 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

845 generic and 664 brand-name prescriptions · $8,446,299 in drug cost · 31 antibiotic prescriptions.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Vyndamax278$7,106,775$25,564
Vyndaqel41$984,809$24,020
Jardiance113$113,829$1,007
Farxiga76$60,736$799
Eliquis45$47,181$1,048
See all 27 drugs
Every Part D drug this clinician prescribed
Vyndamax278$7,106,775$25,564
Vyndaqel41$984,809$24,020
Jardiance113$113,829$1,007
Farxiga76$60,736$799
Eliquis45$47,181$1,048
Entresto31$28,470$918
Wegovy15$20,666$1,378
Xarelto14$9,767$698
Mycophenolate Mofetil15$3,695$246
Tacrolimus18$3,166$176
Incruse Ellipta11$3,019$274
Potassium Chloride27$1,757$65
Bumetanide40$1,528$38
Spironolactone116$1,192$10
Atorvastatin56$764$14
Metoprolol52$725$14
Rosuvastatin20$660$33
Warfarin27$561$21
Ceftriaxone22$537$24
Carvedilol33$487$15
Losartan45$430$10
Hydralazine32$391$12
Ezetimibe12$357$30
Furosemide46$259$6
Amlodipine Besylate44$154$4
Pravastatin11$132$12
Gabapentin20$90$4

Year by year

Part D prescribing by year
20241,509203None44%$8,446,299
20231,501204None27%$2,969,045
20221,1451660% (0)None$1,736,790
20219971270% (0)None$1,782,495
20209581310% (0)20%$1,270,060
20196361150% (0)None$1,528,772
2018197570% (0)None$251,115
201423None0% (0)None$1,675
20133517NoneNone$4,316

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 38 drugs

Part D drugs prescribed in 2023
Vyndamax78$2,063,837$26,459
Opsumit14$180,159$12,868
Adcirca17$69,695$4,100
Farxiga69$65,658$952
Jardiance45$56,588$1,258
Entresto62$50,364$812
Eliquis51$44,230$867
Everolimus18$43,700$2,428
Posaconazole11$32,956$2,996
Sildenafil Citrate15$16,323$1,088
Xarelto11$13,901$1,264
Tacrolimus39$7,885$202
Mycophenolate Mofetil26$5,532$213
Potassium Chloride24$2,340$98
Ceftriaxone37$1,961$53
Bumetanide47$1,390$30
Atorvastatin73$1,312$18
Torsemide11$1,185$108
Isosorbide Mononitrate Er29$1,154$40
Rosuvastatin25$1,148$46
Spironolactone95$1,109$12
Metoprolol64$1,024$16
Losartan50$1,023$20
Carvedilol40$919$23
Hydralazine39$912$23
Warfarin24$889$37
Ezetimibe14$597$43
Pravastatin16$542$34
Bisoprolol18$492$27
Eplerenone11$474$43
Digoxin19$462$24
Furosemide27$401$15
Omeprazole18$368$20
Amlodipine Besylate28$363$13
Amiodarone11$333$30
Prednisone15$129$9
Lisinopril17$86$5
Amoxicillin11$21$2

2022: 30 drugs

Part D drugs prescribed in 2022
Uptravi30$699,988$23,333
Opsumit24$295,601$12,317
Letairis14$154,856$11,061
Adcirca23$96,704$4,205
Tadalafil33$48,986$1,484
Entresto52$46,319$891
Farxiga42$32,104$764
Eliquis27$19,775$732
Jardiance13$12,758$981
Tacrolimus56$10,601$189
Potassium Chloride29$2,235$77
Mycophenolate Mofetil11$1,548$141
Bumetanide41$1,170$29
Rosuvastatin20$917$46
Atorvastatin77$894$12
Carvedilol58$840$14
Torsemide17$839$49
Isosorbide Mononitrate Er44$777$18
Warfarin14$702$50
Bisoprolol14$689$49
Spironolactone62$520$8
Digoxin21$484$23
Hydralazine25$458$18
Metoprolol31$410$13
Gabapentin12$351$29
Losartan28$349$12
Furosemide36$277$8
Clonidine16$214$13
Amlodipine Besylate18$105$6
Lisinopril11$41$4

2021: 33 drugs

Part D drugs prescribed in 2021
Uptravi30$699,188$23,306
Vyndamax13$250,345$19,257
Opsumit20$235,973$11,799
Vyndaqel12$226,188$18,849
Entresto53$50,069$945
Ambrisentan12$46,884$3,907
Tadalafil21$41,271$1,965
Everolimus13$36,415$2,801
Eliquis14$10,519$751
Tacrolimus31$7,896$255
Enoxaparin13$4,254$327
Bumetanide26$2,138$82
Mycophenolate Mofetil11$1,434$130
Eplerenone20$1,403$70
Isosorbide Dinitrate12$1,236$103
Bisoprolol13$1,216$94
Potassium Chloride21$1,037$49
Isosorbide Mononitrate Er40$926$23
Torsemide18$743$41
Carvedilol42$649$15
Hydralazine38$633$17
Atorvastatin46$613$13
Warfarin12$380$32
Metoprolol25$351$14
Spironolactone40$334$8
Rosuvastatin18$314$17
Digoxin30$312$10
Omeprazole21$272$13
Losartan18$244$14
Pantoprazole18$225$12
Furosemide45$177$4
Allopurinol16$70$4
Lisinopril17$68$4

2020: 33 drugs

Part D drugs prescribed in 2020
Uptravi23$451,621$19,636
Vyndaqel22$440,010$20,000
Sandostatin Lar Depot12$52,206$4,351
Ambrisentan16$45,196$2,825
Entresto27$23,888$885
Alyq20$10,214$511
Tacrolimus28$7,077$253
Basaglar Kwikpen U-10016$5,461$341
Enoxaparin19$4,103$216
Potassium Chloride33$2,680$81
Eplerenone22$2,315$105
Bumetanide28$1,874$67
Sildenafil Citrate16$1,529$96
Warfarin41$1,295$32
Isosorbide Mononitrate Er45$846$19
Atorvastatin44$709$16
Metoprolol40$597$15
Bisoprolol22$560$25
Doxycycline Hyclate13$479$37
Torsemide33$476$14
Spironolactone38$392$10
Hydralazine18$301$17
Carvedilol22$267$12
Omeprazole11$244$22
Losartan29$234$8
Lansoprazole17$205$12
Furosemide21$200$10
Gabapentin13$180$14
Digoxin12$172$14
Amlodipine Besylate38$150$4
Lisinopril20$122$6
Sulfamethoxazole-Trimethoprim17$70$4
Fluconazole11$64$6

2019: 22 drugs

Part D drugs prescribed in 2019
Uptravi41$938,224$22,884
Opsumit15$153,393$10,226
Adcirca13$57,114$4,393
Tadalafil16$37,045$2,315
Sildenafil Citrate12$8,116$676
Entresto16$7,812$488
Alyq20$2,030$102
Bumetanide19$1,960$103
Potassium Chloride22$1,241$56
Duloxetine11$844$77
Isosorbide Mononitrate Er16$739$46
Metoprolol16$658$41
Atorvastatin35$587$17
Spironolactone44$353$8
Warfarin17$346$20
Digoxin21$293$14
Pravastatin12$245$20
Carvedilol40$243$6
Losartan15$157$10
Amlodipine Besylate24$126$5
Lisinopril11$96$9
Furosemide13$89$7

2018: 3 drugs

Part D drugs prescribed in 2018
Atorvastatin12$377$31
Spironolactone14$134$10
Carvedilol20$112$6

Money from drug and device companies

$3,341 in 2025

Industry payments by year
202536$2,520$3,341
202457$4,650$15,087
2023621$16,036$18,129
202233$2,930$3,056
202122None$50
202011None$144
2019615None$1,138

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Alnylam PharmaceuticalsAmvuttra$3,130
2 payments
  • Paid to speak or teach for Amvuttra · 2025-10-16 · $2,520
  • Travel for Amvuttra · 2025-09-13 · $610
Abbott LaboratoriesCardiomems$172
3 payments
  • Meals for Cardiomems · 2025-11-10 · $123
  • Meals for Cardiomems · 2025-11-10 · $25
  • Meals for Cardiomems · 2025-11-10 · $25
EndotronixCordella Pulomonary Artery Pressure Sensor$39
1 payment
  • Meals for Cordella Pulomonary Artery Pressure Sensor · 2025-11-12 · $39
See all 6 published payments
Every published payment
EndotronixMeals · 2025-11-12Cordella Pulomonary Artery Pressure Sensor$39
Abbott LaboratoriesMeals · 2025-11-10Cardiomems$123
Abbott LaboratoriesMeals · 2025-11-10Cardiomems$25
Abbott LaboratoriesMeals · 2025-11-10Cardiomems$25
Alnylam PharmaceuticalsPaid to speak or teach · 2025-10-16Amvuttra$2,520
Alnylam PharmaceuticalsTravel · 2025-09-13Amvuttra$610
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $15,087

Payments by company in 2024
PfizerNone$10,000
1 payment
  • Grant · 2024-11-25 · $10,000
Novo NordiskNone$4,650
2 payments
  • Consulting · 2024-12-04 · $3,100
  • Consulting · 2024-07-08 · $1,550
AmgenRepatha$165
1 payment
  • Meals for Repatha · 2024-10-14 · $165
Alnylam PharmaceuticalsOnpattro$146
2 payments
  • Meals · 2024-03-21 · $24
  • Meals for Onpattro · 2024-03-19 · $123
Actelion Pharmaceuticals USNone$125
1 payment
  • Meals · 2024-09-20 · $125

2023: $18,129

Payments by company in 2023
Novo NordiskNone$15,773
3 payments
  • Travel · 2023-12-06 · $195
  • Travel · 2023-12-06 · $272
  • Consulting · 2023-12-06 · $15,306
Abbott LaboratoriesThoratec Heartmate 3 Lvas Implant Kit$1,499
14 payments
  • Travel for Thoratec Heartmate 3 Lvas Implant Kit · 2023-10-23 · $125
  • Travel for Thoratec Heartmate 3 Lvas Implant Kit · 2023-10-23 · $339
  • Travel for Thoratec Heartmate 3 Lvas Implant Kit · 2023-10-02 · $498
  • Travel for Thoratec Heartmate 3 Lvas Implant Kit · 2023-10-02 · $9
  • Meals for Thoratec Heartmate 3 Lvas Implant Kit · 2023-09-27 · $5
  • Meals for Thoratec Heartmate 3 Lvas Implant Kit · 2023-09-27 · $37
  • Meals for Thoratec Heartmate 3 Lvas Implant Kit · 2023-09-27 · $169
  • Meals for Thoratec Heartmate 3 Lvas Implant Kit · 2023-09-27 · $13
  • Meals for Thoratec Heartmate 3 Lvas Implant Kit · 2023-09-27 · $16
  • Meals for Thoratec Heartmate 3 Lvas Implant Kit · 2023-09-27 · $43
  • Meals for Thoratec Heartmate 3 Lvas Implant Kit · 2023-09-27 · $16
  • Meals for Thoratec Heartmate 3 Lvas Implant Kit · 2023-09-27 · $16
  • Meals for Thoratec Heartmate 3 Lvas Implant Kit · 2023-09-21 · $32
  • Meals for Cardiomems · 2023-03-16 · $178
E.R. Squibb & Sons L.L.C.None$730
1 payment
  • Consulting · 2023-01-12 · $730
Alnylam PharmaceuticalsAmvuttra$82
1 payment
  • Meals for Amvuttra · 2023-11-08 · $82
Paragonix TechnologiesParagonix Sherpapak Cardiac Transport System$41
1 payment
  • Meals for Paragonix Sherpapak Cardiac Transport System · 2023-09-09 · $41
NuwellisAquadex Smartflow Console$5
1 payment
  • Meals for Aquadex Smartflow Console · 2023-10-26 · $5

2022: $3,056

Payments by company in 2022
PfizerVyndaqel$2,200
1 payment
  • Honoraria for Vyndaqel · 2022-08-04 · $2,200
E.R. Squibb & Sons L.L.C.None$730
1 payment
  • Consulting · 2022-07-19 · $730
Abbott LaboratoriesCardiomems$126
1 payment
  • Meals for Cardiomems · 2022-10-25 · $126

2021: $50

Payments by company in 2021
Abbott LaboratoriesCentrimag$27
1 payment
  • Meals for Centrimag · 2021-10-27 · $27
LivaNova USALifesparc System$22
1 payment
  • Meals for Lifesparc System · 2021-01-27 · $22

2020: $144

Payments by company in 2020
Boston ScientificResonate$144
1 payment
  • Meals for Resonate · 2020-02-22 · $144

2019: $1,138

Payments by company in 2019
Medtronic VascularHeartware Hvad$494
6 payments
  • Meals for Heartware Hvad · 2019-04-05 · $138
  • Meals for Heartware Hvad · 2019-03-01 · $49
  • Meals for Heartware Hvad · 2019-03-01 · $30
  • Meals for Heartware Hvad · 2019-03-01 · $79
  • Meals for Heartware Hvad · 2019-02-28 · $57
  • Meals for Heartware Hvad · 2019-02-28 · $141
Abbott LaboratoriesHeartmate 3 Left Ventricular Dev$297
4 payments
  • Meals for Mitra Clip System · 2019-06-05 · $143
  • Meals for Heartmate 3 Left Ventricular Dev · 2019-04-04 · $138
  • Travel for Heartmate 3 Left Ventricular Dev · 2019-04-04 · $9
  • Travel · 2019-04-04 · $8
Actelion Pharmaceuticals USBosentan$223
2 payments
  • Meals · 2019-07-31 · $123
  • Meals for Bosentan · 2019-04-03 · $100
Alnylam PharmaceuticalsNone$95
1 payment
  • Meals · 2019-09-25 · $95
United TherapeuticsOrenitram$22
1 payment
  • Meals for Orenitram · 2019-04-03 · $22
PfizerVyndaqel$8
1 payment
  • Education for Vyndaqel · 2019-08-06 · $8

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
ENDOTRONIX, INC. · Proactive-Hf · 2023Their institution$226,151
Alexion Pharmaceuticals, Inc. · A Phase 3,Radomized,Double-Blind,Placebo-Controlled,Multicenter Study To Evaluate the Efficacy and Safety of Amyloid Depleter Alxn2220 in Adult Participants Wiith Transthyretin Amyloid Cardiomyopathy Attr Cm · 2025Their institution$175,872
ENDOTRONIX, INC. · Proactive-Hf · 2024Their institution$161,174
ENDOTRONIX, INC. · Proactive-Hf · 2022Their institution$110,893
ENDOTRONIX, INC. · Proactive-Hf · 2025Their institution$84,426
ENDOTRONIX, INC. · Proactive-Hf · 2021Their institution$79,440
ENDOTRONIX, INC. · Proactive-Hf · 2020Their institution$48,017
Ionis Pharmaceuticals, Inc. · A Phase 3 Global Doubleblind Randomized Placebocontrolled Study To Evaluate the Efficacy and Safety of Ion682884 in Patients With Transthyretinmediated Amyloid Cardiomyopathy Attrcm · 2025Their institution$39,741
Actelion Pharmaceuticals, Ltd · Opsumit · 2019Their institution$32,524
Eidos Therapeutics, Inc. · A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (Act-Early Trial) · 2025Their institution$30,107
Medtronic, Inc. · Psr-Mcs · 2021Their institution$30,050
Medtronic, Inc. · Psr-Mcs · 2020Their institution$29,505
Medtronic, Inc. · Psr-Mcs · 2019Their institution$19,439
PFIZER INC. · A Phase 3 Multicenter Randomized Doubleblind Extension Study To Evaluate the Safety of Daily Oral Dosing of Tafamidis Meglumine Pf06291826 20 Mg Or 80 Mg in Subjects Diagnosed With Transthyretin Cardiomyopathy Ttrcm · 2020Their institution$17,357
Medtronic, Inc. · Psr-Mcs · 2022Their institution$15,003
AstraZeneca UK Limited · A Non-Interventional, Prospective, Multi-Country Study Collecting Real-World Data on the Characteristics, Treatment Patterns, and Outcomes of Patients With Amyloid Transthyretin (Attr) Amyloidosis · 2025Their institution$14,674
Janssen Research & Development, LLC · Uptravi Selexipag the Users Drug Registry · 2021Their institution$14,250
Actelion Pharmaceuticals, Ltd · Clinical Study To Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation · 2020Their institution$13,070
AstraZeneca UK Limited · A Non-Interventional, Prospective, Multi-Country Study Collecting Real-World Data on the Characteristics, Treatment Patterns, and Outcomes of Patients With Amyloid Transthyretin (Attr) Amyloidosis · 2024Their institution$12,977
Ionis Pharmaceuticals, Inc. · An Openlabel Extension Study To Assess the Longterm Safety of Eplontersen Ion682884 in Patients With Transthyretinmediated Amyloid Cardiomyopathy Attrcm · 2025Their institution$9,725
Janssen Research & Development, LLC · Uptravi (Selexipag): the Users Drug Registry · 2020Their institution$6,650
Medtronic, Inc. · Psr-Mcs · 2025Their institution$5,968
PFIZER INC. · A Phase 3 Multicenter Openlabel Study To Evaluate the Safety of Daily Oral Dosing of Tafamidis Meglumine Pf0629182683 20 Mg Or 80 Mg Or Tafamidis Pf0629182600 61 Mg in Subjects Diagnosed With Transthyretin Cardiomyopathy Attrcm · 2021Their institution$4,239
Janssen Research & Development, LLC · Uptravi Selexipag the Users Drug Registry · 2022Their institution$3,680
Medtronic, Inc. · Dt Pas · 2020Their institution$2,455
PFIZER INC. · A Phase 3 Multicenter Randomized Doubleblind Extension Study To Evaluate the Safety of Daily Oral Dosing of Tafamidis Meglumine Pf06291826 20 Mg Or 80 Mg in Subjects Diagnosed With Transthyretin Cardiomyopathy Ttrcm · 2019Their institution$1,901
Medtronic, Inc. · Psr-Mcs · 2024Their institution$1,456
Medtronic, Inc. · Psr-Mcs · 2023Their institution$1,290
AstraZeneca UK Limited · A Phase I/II Open-Label Study To Evaluate the Safety, Cellular Kinetics and Efficacy of Azd5851, A Chimeric Antigen Receptor T Cell (Car-T) Therapy Directed Against Gpc3 in Adult Participants With Advanced/Recurrent Hepatocellular Carcinoma · 2025Their institution$1,120
Medtronic, Inc. · Dt Pas · 2021Their institution$858
PFIZER INC. · A Phase 3 Multicenter Openlabel Study To Evaluate the Safety of Daily Oral Dosing of Tafamidis Meglumine Pf0629182683 20 Mg Or 80 Mg Or Tafamidis Pf0629182600 61 Mg in Subjects Diagnosed With Transthyretin Cardiomyopathy Attrcm · 2022Their institution$609
Medtronic, Inc. · Apogee · 2020Their institution$533
Medtronic Vascular, Inc. · Psr-Mcs · 2019Their institution$375

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
75.0 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1720377146
Licence
CA A130155California A130155: Current · expires 2027-10-31
Trained
University of Pittsburgh School of Medicine, 2011 · 15 years ago
Group
University of California San Francisco · Regents of the University of California
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207RA0001X (207RA0001X); Internal medicine (207R00000X); Cardiology (207RC0000X)
Mailing address
UCSF Division of Cardiology, 505 Parnassus Ave. Rm M1184, San Francisco, CA, 94143
NPI first listed
2011-04-06
NPI last updated
2021-09-16
NPI record certified
2021-09-16

This is when the NPI record was last certified, not a medical board exam.